Join

Compare · FMS vs LSTA

FMS vs LSTA

Side-by-side comparison of Fresenius Medical Care AG (FMS) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FMS and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
  • FMS is the larger of the two at $12.72B, about 440.0x LSTA ($28.9M).
  • Over the past year, FMS is down 9.1% and LSTA is up 31.6% - LSTA leads by 40.7 points.
  • LSTA has been more active in the news (2 items in the past 4 weeks vs 1 for FMS).
  • FMS has more recent analyst coverage (21 ratings vs 0 for LSTA).
PerformanceFMS-9.14%LSTA+31.56%
2025-04-28+0.00%2026-04-24
MetricFMSLSTA
Company
Fresenius Medical Care AG
Lisata Therapeutics Inc.
Price
$22.76+0.02%
$3.21-3.89%
Market cap
$12.72B
$28.9M
1M return
+2.18%
-36.12%
1Y return
-9.14%
+31.56%
Industry
Misc Health and Biotechnology Services
Misc Health and Biotechnology Services
Exchange
NYSE
NASDAQ
IPO
News (4w)
1
2
Recent ratings
21
0
FMS

Fresenius Medical Care AG

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.